🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 19 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/01/2022 39,50 40,50 38,58 38,82 -3,12% 4,86% 709.200
20/01/2022 41,27 42,22 40,06 40,07 -2,60% 5,22% 977.000
19/01/2022 41,46 43,02 41,01 41,14 -0,72% 4,85% 488.000
18/01/2022 43,13 44,10 41,42 41,44 -5,28% 6,21% 769.200
14/01/2022 42,12 44,03 41,29 43,75 +3,60% 6,52% 1.494.000
13/01/2022 40,85 42,98 40,82 42,23 +2,62% 5,29% 820.800
12/01/2022 40,00 41,60 39,14 41,15 +1,76% 6,15% 1.597.600
11/01/2022 40,31 42,37 40,27 40,44 +1,02% 5,21% 1.334.500
10/01/2022 37,95 41,16 37,54 40,03 +5,07% 9,54% 2.001.400
07/01/2022 38,53 39,43 37,65 38,10 -2,08% 4,61% 1.302.400
06/01/2022 37,75 39,70 37,24 38,91 +1,12% 6,52% 1.372.700
05/01/2022 40,39 41,94 38,43 38,48 -5,94% 8,69% 1.302.700
04/01/2022 42,49 43,78 40,23 40,91 -3,92% 8,34% 1.220.200
03/01/2022 39,95 42,63 38,79 42,58 +6,90% 9,61% 1.439.700
31/12/2021 39,97 41,45 39,58 39,83 -0,62% 4,68% 1.215.400
30/12/2021 40,50 42,00 39,93 40,08 -1,31% 5,12% 1.084.900
29/12/2021 40,42 40,74 39,96 40,61 +0,47% 1,93% 223.100
28/12/2021 41,05 41,90 40,03 40,42 -1,53% 4,56% 324.400
27/12/2021 41,73 42,04 40,84 41,05 -1,94% 2,86% 357.600
23/12/2021 40,85 42,15 40,63 41,86 +2,47% 3,73% 331.700
22/12/2021 39,88 40,99 38,62 40,85 +1,90% 5,94% 270.200
21/12/2021 40,35 41,07 39,30 40,09 -0,42% 4,39% 294.800
20/12/2021 38,88 40,75 37,75 40,26 +2,94% 7,72% 391.600
17/12/2021 36,57 39,33 36,49 39,11 +6,92% 7,78% 886.000
16/12/2021 38,17 38,85 36,39 36,58 -3,76% 6,43% 515.900
15/12/2021 37,08 38,07 35,95 38,01 +2,54% 5,72% 487.200
14/12/2021 36,22 37,36 36,05 37,07 +1,70% 3,63% 354.800
13/12/2021 35,01 37,01 35,00 36,45 +3,05% 5,74% 486.800
10/12/2021 36,10 36,36 34,85 35,37 -1,61% 4,18% 567.700
09/12/2021 37,83 37,98 35,51 35,95 -5,91% 6,53% 545.500